

Page 1 of 4

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B:
For other lines of business:
Please use commercial form.
Note: Daxxify, Dysport and
Myobloc are non-preferred.
The preferred products are
Botox and Xeomin.

Would you like to use electronic prior authorization? Consider using **Availity**, our electronic prior authorization portal. Learn more about **Availity** from the links in the table below.

For phone or fax requests, refer to the table below for routing information. To determine which box to use, refer to the patient's Aetna ID card. State specific special needs and Medicare-Medicaid Plans may be designated on the front of the ID card or in the website URL on the back of the card. If you don't see your specific plan listed, call the number on the back of the member's ID card to confirm routing information.

For **Aetna Medicare Advantage** and **Allina Health Aetna Medicare** members send request to:

Phone: <u>1-866-503-0857</u> (TTY: <u>711</u>)

Fax: <u>1-844-268-7263</u>

Availity: https://www.aetna.com/health-care-professionals/resource-center/availity.html

For Aetna Medicare Advantage Virginia Dual Eligible Special Needs Plans (HMO D-SNP)

send request to:

Phone: <u>1-855-463-0933</u> Fax: <u>1-833-280-5224</u>

Availity: https://www.aetnabetterhealth.com/virginia-hmosnp/providers/portal

For Aetna Assure Premier Plus Medicare Advantage New Jersey Dual Eligible Special Needs Plans

(HMO D-SNP) send request to:

Phone: <u>1-844-362-0934</u> Fax: <u>1-833-322-0034</u>

Availity: https://www.aetnabetterhealth.com/new-jersey-hmosnp/providers/portal.html

For Aetna Better Health of Illinois Premier Medicare Medicaid Plan (MMP) send request to:

Phone: <u>1-866-600-2139</u> FAX: 1-855-320-8445

Availity: https://www.aetnabetterhealth.com/illinois/providers/portal

For Aetna Better Health of Ohio Premier Medicare Medicaid Plan (MMP) send request to:

Phone: <u>1-855-364-0974</u> Fax: <u>1-855-734-9389</u>

Availity: https://www.aetnabetterhealth.com/ohio/providers/portal

For Aetna Better Health of Michigan Premier Medicare Medicaid Plan (MMP) send request to:

Phone: <u>1-855-676-5772</u> Fax: <u>1-844-241-2495</u>

Availity: https://www.aetnabetterhealth.com/michigan/providers/portal.html



Page 2 of 4

For Medicare Advantage Part B: For other lines of business: Please use commercial form.

Note: Daxxify, Dysport and Myobloc are non-preferred. The preferred products are Botox and Xeomin.

Please indicate: Start	•	completed and legible for p //	recertification review.)				
		of last treatment/	/				
Precertification Requested	d By:		Phone:		Fax:		
A. PATIENT INFORMATION	N						
First Name:		Last Name:		DOB:			
Address:		С	ity:	State:	ZIP:		
Home Phone:	Work Phone:	Cell Pho	ne:	Email:	1		
Patient Current Weight:	lbs or kgs Pati	ient Height: inches	or cms Allergi	es:			
B. INSURANCE INFORMAT		<u> </u>					
	· · · · · · · · · · · · · · · · · · ·		Does patient have other coverage? ☐ Yes ☐ No				
Group #:		If yes, provide ID#:					
Insured:		Insured:			_		
C. PRESCRIBER INFORMA	ATION						
First Name:		Last Name:	((Check One): 🔲 N	M.D. 🔲 D.O. 🔲 N.P. 🔲 P.A.		
Address:			City:	State:	ZIP:		
Phone:	Fax:	St Lic #:	NPI#:	DEA #:	UPIN:		
Provider Email:		Office Contact Name:	1111111111	Phone:			
D. DISPENSING PROVIDER	R/ADMINISTRATION INF			i ilolio.			
Place of Administration:	VADIMINIOTRATION IN	ORMATION	Dispensing Provider/F	Pharmacy:			
Self-administered Ph	vsician's Office	e	☐ Outpatient Dialysis		cian's Office		
☐ Outpatient Infusion Center			☐ Retail Pharmacy		alty Pharmacy		
Center Name:			☐ Mail Order	•	: <u> </u>		
☐ Home Infusion Center	Phone:		Name:				
Agency Name: Administration code(s) (CP	DT\·		Address:				
Address:					ZIP:		
City:		ZIP:					
Phone:					X:		
TIN:					N:		
NPI:			NPI:				
E. PRODUCT INFORMATION	ON						
Request is for Botox	Dysport ☐ Myobloc ☐	☐ Xeomin ☐ Daxxify D o	ose:	Frequency:			
HCPCS Code:		_ **Please note - requests o			-		
F. DIAGNOSIS INFORMAT	ION - Please indicate prim	nary ICD code and specify	any other where applica	able.	·		
Primary ICD Code:	•	Secondary ICD Code	:	Other ICD Cod	de:		
G. CLINICAL INFORMATIO	N - Required clinical infor	mation must be completed	l in its entirety for all pre	 certification reques	sts.		
For Initiation Requests (clini-				,			
Note: Daxxify, Dysport and I			are Botox and Xeomin.				
☐ Yes ☐ No Has the patien	nt had prior therapy with the	requested product within the	ne last 365 days?				
☐ No Has the patient had a trial and failure of any of the following? (if yes, select all that apply below)							
	abotulinumtoxinA) 🔲 Xeo						
	e member's trial and failure						
	be the nature of the failure			1			
	nt nad an adverse reaction abotulinumtoxinA) □ Xeoi	to any of the following? (if ye	es, select all that apply be	elow)			
	e member's adverse reaction						
		e reaction to the preferred d					
					ed products when indicated for		
the patient's diagnosis (select	all that apply)		•	01	'		
☐ Botox (onabotulinumtoxinA		mtoxinA)?					
140.1.60.60.		0.000.1.1.1					
Which of the following is the	. •	•		• /	contractions of the ambients		
□ biepnarospasm – □ Yes		ave intermittent or sustained iding Blepharospasm associ			contractions of the orbicularis harospasm)?		
	2041 114000 (1100	g =piai.copaoiii accoo	ayotoma ana be	д сэсстаат ыср			



Page 3 of 4

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B: For other lines of business: Please use commercial form.

Note: Daxxify, Dysport and Myobloc are non-preferred. The preferred products are Botox and Xeomin.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB				
G CLINICAL INFORMATION (contin	qued) - Required clinical information must	he completed in its entirety for	r all precertification requests				
G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests. Cervical dystonia (spasmodic torticollis) of moderate or greater severity- Please check all that apply: Clonic and/or tonic involuntary contractions of multiple neck muscles							
☐ Sustained head torsion and/or tilt with limited range of motion in the neck ☐ Alternative causes of symptoms have been ruled out, including chronic neuroleptic treatment, contractures, or other neuromuscular disorders Please indicate the duration the symptoms have persisted: months							
☐ Chronic anal fissure - Please indica	te the duration the patient has experienced the esponsive to conservative therapeutic measu		topical diltiazem cream)				
☐ Criopharyngeal dysfunction ☐ Yes ☐ No Is the patient a can ☐ Yes ☐ No Is the patient a can	didate for surgery? didate for endoscopic balloon dilation?						
□ Esophageal achalasia – Please check all that apply: □ At high risk of complications of pneumatic dilation or surgical myotomy □ Advanced age or limited life expectancy □ Failed conventional therapy □ Epiphrenic diverticulum or hiatal hernia, both of which increase the risk of dilation-induced perforation □ Sigmoid-shaped esophagus □ Failed a prior myotomy or dilation □ Previous dilation-induced perforation □ Other: □							
☐ First Bite Syndrome – Please check ☐ Experienced persistent symptom							
☐ Failed trial of analgesics - Please☐ Failed trial of antidepressants - F	e provide name and date range used: Name: Please provide name and date range used: Na es, please provide the date range used: Date	ame: D	ate range:ate range:				
☐ Facial myokymia and trismus associ		<u> </u>					
☐ Frey's syndrome ☐ Focal dystonias – Please check all the	hat apply:						
	onia, characterized by dystonic movements in ☐ Focal d	stonias in corticobasilar degen					
☐ Focal hand dystonias (i.e. writer's of ☐ Abnormal muscle tone causing p	cramp) – Please check all that apply: persistent pain and/or interfering with functions	al ability ☐ Failure of conserv	vative medical therapy				
☐ Hirschsprung's disease with interna☐ Hyperhidrosis	ıl sphincter achalasia following endorectal pull	-through.					
Yes No Does the patient ha	ave intractable, disabling focal primary hyperh t location?						
Please check all symptoms that apply: Member is unresponsive or unable to tolerate pharmacotherapy prescribed for excessive sweating if sweating is episodic Significant disruption of professional and/or social life has occurred because of excessive sweating Topical aluminum chloride or other extra-strength antiperspirants are ineffective or result in a severe rash							
☐ Laryngeal spasm							
☐ Limb spasticity – Please check all that apply: ☐ Upper limb spasticity ☐ Limb spasticity due to multiple sclerosis ☐ Hereditary spastic paraplegia ☐ Spastic hemiplegia, such as due to stroke or brain injury							
Equinus varus deformity or other lower limb spasticity in children with cerebral palsy Yes No Does the patient have evidence of the absence of significantly fixed deformity?							
Limb spasticity due to other demyelinating diseases of the central nervous system (including adductor spasticity and pain control in children undergoing adductor-lengthening surgery, as well as children with upper extremity spasticity)							
 ☐ Documentation of abnormal muscle tone interfering with functional ability or is expected to result in joint contracture with future growth ☐ Documented failure to standard medical treatments ☐ Surgical intervention is the last option ☐ Treatment being requested to enhance function or to allow additional therapeutic modalities to be employed 							
☐ Medically refractory upper extremity tremor — ☐ Yes ☐ No Does the condition interfere with activities of daily living (ADLs)?							
For <i>continuation of therapy:</i> Yes No Has the patient responded to a trial of botulinum toxin that has enabled ADLs or communication? Migraines – Please check all that apply:							
☐ 5 or more migraine attacks without aura ☐ Duration of the attacks lasted 4 hours to 3 days ☐ 2 or more migraine attacks with aura ☐ Prevention of chronic (more than 14 days per month) of migraines							
Yes No Has the patient had 2 or more of the following: aggravation by or causing avoidance of routine physical activity; moderate or severe pain intensity; pulsating; and/or unilateral (affecting half the head)?							
Yes No Is the patient an adult who has tried and failed at least 3 medications selected from at least two classes of migraine headache							
prophylaxis medications for at least 2 months (60 days) for each medication?							
Indicate the drug of	classes that were tried:	RBs	☐ Anti-epileptic drugs ☐ Calcium channel blockers				



Page 4 of 4

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B: For other lines of business: Please use commercial form.

Note: Daxxify, Dysport and Myobloc are non-preferred. The preferred products are Botox and Xeomin.

Patient First Name	Patient Last Name	Patient Phone	Patient DOB				
G. CLINICAL INFORMATION (co	ntinued) – Required clinical inform	ation must be completed in its entire	aty for all precertification requests				
For migraine continuation requests		enon must be completed in its entire	ty for all precentification requests.				
		ced by at least 7 days per month by th	e end of the initial trial?				
☐ Yes ☐ No Has the duration of the migraine headaches been reduced by at least 100 total hours per month by the end of the initial trial?							
	■ Neurogenic detrusor over activity - □ Yes □ No Is the condition resulting from multiple sclerosis, spinal cord injury, or other neurologic condition? If yes, please select diagnosis: □ Multiple Sclerosis □ spinal cord injury □ other neurologic condition - specify:						
		jury otner neurologic condition – s urodynamic testing					
	Failure/intolerance to at least one ad	equately titrated anticholinergic medica	tion (e.g. oxybutynin chloride, trospium chloride) Date:				
☐ Documented failure	intolerance to an OTC bladder medic	ation (oxybutynin transdermal patch (0					
─────────────────────────────────────			Date:				
Overestive bladder	Medication	#2:	Date:				
Overactive bladder	c antibiotics be administered 1-3 days	prior to treatment, on the treatment d	av. and 1-3 days post-treatment?				
	ed medication be used in combination		ay, and i o days post a same				
Please check all that apply:							
☐ Symptoms of urinar ☐ Documented behav	y incontinence, urgency, and frequence	су					
	cute urinary tract infection or acute ur	inary retention					
☐ Documented failure	intolerance to adequately titrated ove	ractive bladder medications (e.g., oxy	butynin, trospium, Myrbetriq [®] , Vesicare [®])				
Please provide			Date:				
			Date: Date:				
☐ Painful Bruxism	Medical	011 #3.	Date				
☐ Palatal Myclonus with disabling s	ymptoms (e.g., objective, intrusive cli	cking tinnitus)					
☐ Post-facial (7th cranial) nerve pa	lsy synkinesis (hemifacial spasms)						
	characterized by sudden, unilateral, s	ynchronous contractions of muscles in	nervated by the facial nerve?				
Post-parotidectomy sialocele	failed conservative management?						
	ich type of conservative managemen	t treated failed: ☐ Antibiotic					
	,,	\longrightarrow Please provide	e name of antibiotic and date ranged used:				
			: Date:				
		☐ Pressure dressing ☐ Serial percutaneou	is needle asniration				
			pe- specify:				
☐ Ptyalism/sialorrhea (excessive se		neck all that apply:					
☐ Refractory to pharmacotherapt ☐ Documentation of medically topical treatments or hygiene	significant complications of sialorrhea	, such as chronic skin maceration or ir	nfections that cannot be controlled with				
☐ Strabismus (esotropia horizontal	for deviations < 50 prism diopters, ve	rtical strabismus or persistent cranial r hilder's disease) – <i>Please check all th</i>	nerve VI palsies (including gaze palsies at apply:				
☐ Uncorrected congenital strab ☐ Medication being prescribed ☐ Other Condition – Please a	ismus or no binocular fusion Pr as an alternative to surgery Int	•	Spontaneous recovery of strabismus unlikely				
H. ACKNOWLEDGEMENT							
Request Completed By (Signatur	re Required):		Date: /				
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.							

The plan may request additional information or clarification, if needed, to evaluate requests.